Elevation Oncology, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 95.08 million compared to USD 32.04 million a year ago. Basic loss per share from continuing operations was USD 4.09 compared to USD 2.64 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.53 USD | -4.08% | -12.19% | +557.36% |
05-31 | Piper Sandler Starts Elevation Oncology With Overweight Rating, $10 Price Target | MT |
05-14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+557.36% | 193M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022